Scholars Central

EditorialPublished 15 Mar 2021

Editorial Note On Hepatocellular Carcinoma

Authors: Prathyusha.k

Journal of Gastroenterology and Digestive Diseases

Volume 6 · Issue 2 · Pages 1–2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

The combination of atezolizumab and bevacizumab showed encouraging anticancer activity and safety in a very section 1b trial involving patients with unresectable hepatoma. In a world, open-label, section three trial, patients with unresectable hepatocarcinoma United Nations agency had not antecedently received general treatment were haphazardly allotted in a very 2:1 quantitative relation to receive either atezolizumab and bevacizumab or sorafenib till unacceptable noxious effects occurred or there was a loss of clinical profit. The coprimary finish points were overall survival and progression-free survival within the intention-to-treat population, as assessed at associate freelance review facility per Response analysis Criteria in Solid Tumors, version 1.1

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Gastroenterology and Digestive Diseases.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Gastroenterology and Digestive Diseases
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Prathyusha.k”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels